Ahold Delhaize share buyback update

Zaandam, the Netherlands, November 17, 2020 – Ahold Delhaize has repurchased 1,772,516 of Ahold Delhaize common shares in the period from November 9, 2020 up to and including November 13, 2020. The shares were repurchased at an average price of €23.15 per share for a total consideration of € 41 million. These repurchases were made as part of the €1 billion share buyback program announced on December 4, 2019.

The total number of shares repurchased under this program to date is 39,941,411 common shares for a total consideration of € 918 million.

Download the share buyback transactions excel sheet for detailed individual transaction information from www.aholddelhaize.com/en/investors/share-information/share-buy-back-programs/

This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.



JPMorgan Chase Commits £2 Million to Boost Black and Ethnic Minority-Led Nonprofits in London

JPMorgan Chase Commits £2 Million to Boost Black and Ethnic Minority-Led Nonprofits in London

London Community Foundation to join effort to increase local organisations’ ability to respond to the impact of COVID-19

Initiative is in line with a long-term commitment to address key drivers of the racial wealth divide, reduce systemic racism, and support employees

LONDON–(BUSINESS WIRE)–
Today, during the Powerlist Black Excellence Awards,JPMorgan Chase willannounce a £2 million philanthropic investment to support nonprofit organisations in London that are led by Black and ethnic minority leaders.

In collaboration with other organisations, including the London Community Foundation, the firm will help boost the ability of local nonprofit organisations to deal with the increased demand for their services since the onset of COVID-19. This collaboration aims to help remove barriers to opportunity for Black and ethnic minority communities by strengthening organisations that focus on jobs and skills, small business growth and financial health.

“The COVID-19 pandemic has had a disproportionate impact on the health and finances of Black and ethnic minority communities, highlighting and exacerbating structural barriers to economic opportunity,” said Viswas Raghavan, CEO of J.P. Morgan in EMEA. “As part of our global commitment to racial equity, JPMorgan Chase is focused on helping develop local, community-driven solutions to help historically underserved Londoners share in the benefits of an inclusive economy.”

Structural barriers in the U.K. have created profound racial inequalities that have been exacerbated by the COVID-19 pandemic. While over half of white groups reported that they had not been affected financially by the coronavirus crisis, only a third of Black and minority ethnic (BME) people said the same. Research shows that BME people are more likely to have found it harder than usual to pay for essentials, meet basic needs (12% BME vs 8% white groups) and pay bills or rent (15% BME vs 8% white groups).

JPMorgan Chase and the London Community Foundationare looking to collaborate with organisations with Black and ethnic minority leaders to design and implement a programme that helps address economic disparity in a targeted and meaningful way. This effort is focused on strengthening local nonprofit organisations that are on the frontlines of addressing the impact of COVID-19 on vulnerable communities.

“This is an important initiative for London’s communities as it seeks to invest in both BME-led frontline organisations, providing vital employment and financial health support, as well as the organisations that can support their resilience and voice,” said Kate Markey, CEO of London Community Foundation. “LCF is delighted to be partnering with J.P. Morgan on the programme at this time.”

This commitment builds on the approach JPMorgan Chase has taken in its support of London Youth to help 15 youth clubs across London empower young people. This increases their employability by building their skills and connecting them with employers.

“Building out our capacity to deliver employability support has allowed us to be more impactful in helping the young people who come to our club,” said Syed Uddin, Head if Operations at Leaders in Community Youth Club in East London. “We are now better able to work with them to pursue their career and education goals. We have been able to exchange ideas with other youth clubs, train staff to offer relevant advice and guidance, access better employability resources online, introduce a skills development framework and use new digital tools for virtual career insight and work experience opportunities.”

A Commitment to Racial Equity

This new effort follows a $30 billion commitment by JPMorgan Chase to advance racial equity through its expertise in business, policy and philanthropy. The commitment will focus on promoting and expanding affordable housing and homeownership, growing Black and ethnic-minority owned small businesses, improving financial health and access to banking, and building a more diverse and inclusive workplace.

In the U.K., through its Advancing Black Pathways Programme, the firm has a history of investing in the careers of Black students and leaders.

About JPMorgan Chase

JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $3.2 trillion and operations worldwide. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. A component of the Dow Jones Industrial Average, JPMorgan Chase & Co. serves millions of customers in the United States and many of the world’s most prominent corporate, institutional and government clients under its J.P. Morgan and Chase brands.

Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.

About London Community Foundation

The London Community Foundation (LCF) exists to help build strong and connected communities. The charity does this by inspiring London’s generosity to invest in small charities and community groups working deep in the Capital’s communities. Since inception it has raised over £100M to support London’s grassroots, working with corporate and individual philanthropists as well as public sector partners. Since first lockdown, LCF has committed over £9M in COVID funding as part of the London Community Response, a collaboration of London funders committed to best practice funding during the crisis as well as being a signatory of #WeStandwiththeSector.

About London Youth

London Youth is a charity on a mission to improve the lives of young people in London, challenging them to be the best they can be. The charity has been championing outstanding youth work for over 130 years, providing young people with opportunities outside education and the home to have fun with their friends, develop their skills, to be healthy, creative and to make positive change in their communities.

Their diverse network of 600+ community youth organisations are located in every borough across the capital. The charity creates opportunities for tens of thousands of young Londoners every year through employability, sports development, arts, social action and outdoor education programmes.

For more information, visit https://londonyouth.org/what-we-do/employability/

Amalia Kontesi, [email protected]

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Professional Services Philanthropy Other Philanthropy Fund Raising Finance Foundation Banking

MEDIA:

Logo
Logo

Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer

Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer

  • Two new studies have received ‘Safe to Proceed’ notifications from the United States Food and Drug Administrations and are pending activation:
    • A phase II study of NBTXR3 activated by radiation and combined with pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma with limited PD-L1 expression or refractory to PD-1 blockade
    • A phase II study of reirradiation with NBTXR3 in patients with inoperable locoregional recurrent head and neck squamous cell carcinoma
  • Following the release of positive first results from the Company’s phase I immunotherapy trial, these trials highlight the continued expansion of the development plan for NBTXR3 in combination with checkpoint inhibitors and could present additional opportunities to accelerate the pipeline

“Overcoming low response rates in cancer immunotherapy is a major opportunity for advancement in our field. Combined with the fact that many patients have no other options if immunotherapy does not work, addressing this unmet medical need is critical to our mission of treating as many patients as possible with NBTXR3. With recent positive results from our phase I I/O trial, the pending activation of two phases II trials evaluating NBTXR3 with checkpoint inhibitors highlights the momentum of NBTXR3 development.” – Laurent Levy, CEO of Nanobiotix

PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Regulatory News:

NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”) (Paris:NANO), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the United States Food and Drug Administration (FDA) has provided ‘Safe to Proceed’ notifications for two additional trials in its ongoing clinical collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson). These trials were co-developed with Nanobiotix and MD Anderson is the sponsor and executor.

Significant Unmet Needs and Opportunity in Cancer Immunotherapy

Cancer immunotherapies such as immune checkpoint inhibitors (ICIs) have shown promising clinical outcomes over the past two decades; and are often used for patients with advanced cancers once other therapies have reached the end of their effectiveness. However, the vast majority of patients only receive a temporary benefit or no benefit from ICIs, as they either develop resistance to the treatment during the course of therapy or are non-responsive to the treatment altogether (only 15%-20% of patients respond, according to published data). These barriers present a significant unmet need to improve the efficacy ICIs and expand their potentially curative benefits to more patients with advanced cancers.

Combining ICIs with radiation therapy is emerging as a valuable strategy to “prime” an immune response and thereby increase the response rate, however the efficacy of radiation therapy is limited by toxicities related to the exposure of healthy tissues.

NBTXR3 is injected one time, directly into solid tumors. The product candidate is designed to increase the energy deposit from radiation therapy within the target tumor and subsequently increase the tumor-killing effect without increasing toxicity in surrounding healthy tissue. Pre-clinical and clinical data also suggest that NBTXR3 activated by radiation therapy can prime the immune system, creating an anti-tumor immune response that produces both local and systemic effects.

A Phase II Study of NBTXR3 Activated by Radiation and Combined with Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Limited PD-L1 Expression or Refractory to PD-1 Blockade

This MD Anderson trial is an open label, two cohort, non-randomized phase II study. The primary objective of the study is to evaluate tumor response of NBTXR3 activated by radiation therapy in combination with pembrolizumab in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

The population includes patients with inoperable R/M HNSCC of the oropharynx, oral cavity, hypopharynx, larynx or neck. Patients could be anti-PD-1/L1 naïve or refractory. Up to 60 patients may be treated, with up to 40 in the first cohort and up to 20 in the second cohort. The first cohort will include anti-PD-1/L1 naïve patients with a combined positive score (CPS) between greater than or equal to 1% and less than 20%. The second cohort will include anti-PD-1/L1 refractory patients irrespective of PD-L1 expression.

A Phase II Study of Reirradiation with NBTXR3 in Patients with Inoperable Locoregional Recurrent Head and Neck Squamous Cell Carcinoma

This MD Anderson trial is an open label, two cohort, non-randomized phase II study. The primary objectives of the study are: (i) to estimate progression-free survival (PFS) and the early clinical benefit in patients treated with NBTXR3 activated by SBRT re-irradiation, with concurrent pembrolizumab; (ii) to assess the safety profile and estimate the early clinical benefit of NBTXR3 activated by a reduced dose of IMRT or IMPT re-irradiation with concurrent pembrolizumab.

The population includes patients with inoperable, locoregional recurrent head and neck squamous cell carcinoma (HNSCC) or second primary HNSCC, previously treated with definitive radiation therapy and without radiographic evidence of metastases. Patients could be anti-PD-1/L1 naïve or non-responders. Up to 80 patients may be treated, with up to 60 in the SBRT cohort and up to 20 in the IMRT/IMPT cohort.

***

About NBTXR3

NBTXR3 is a novel, potentially first-in-class radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The primary mode of action (MoA) of NBTXR3 is designed to generate increased cellular destruction when activated by radiation therapy without increasing damage to healthy tissues. Subsequently, this cellular destruction also triggers an adaptive immune response.

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. In February 2020, the United States Food and Drug Administration granted the regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.

Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company is also engaged in a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to further expand the NBTXR3 development program.

About NANOBIOTIX: www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix’s novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorité des Marchés Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

Nanobiotix

Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

[email protected]

Investor Relations Department

Ricky Bhajun

Senior Manager, Investor Relations

+33 (0)1 79 97 29 99

[email protected]

Media Relations

France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0)6 64 79 97 51

[email protected]

KEYWORDS: France Europe

INDUSTRY KEYWORDS: Oncology FDA Health Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Hologic Announces CE Mark of the Genius™ Digital Diagnostics System for Cervical Cancer Screening

Hologic Announces CE Mark of the Genius™ Digital Diagnostics System for Cervical Cancer Screening

Powerful artificial intelligence combined with digital imaging designed to transform screening

MARLBOROUGH, Mass.–(BUSINESS WIRE)–
Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System is now CE marked in Europe. Genius Digital Diagnostics is the first digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced digital imaging to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116006076/en/

Genius™ Digital Diagnostics System for Cervical Cancer Screening (Photo: Business Wire)

Genius™ Digital Diagnostics System for Cervical Cancer Screening (Photo: Business Wire)

For more than 30 years, Hologic has developed and brought to market new advances in cervical cancer screening, including the first liquid-based cytology technology, the ThinPrep® Pap Test, and the first FDA-approved mRNA-based HPV test, the Aptima® HPV Assay. Hologic is redefining cervical cancer screening yet again by introducing Genius Digital Diagnostics for laboratories. The system can rapidly analyze all cells on a ThinPrep Pap test slide, narrowing tens of thousands of cells down to a gallery view of the most diagnostically relevant images. This will help provide healthcare providers with the critical information they need to guide earlier detection and better treatment decisions for the patients they serve.

“Application of AI requires digital images that are of exceptional quality,” said Kevin Thornal, president, Diagnostic Solutions Division at Hologic. “Our teams developed a breakthrough imaging technology that converts physical glass cytology slides into digital images with superior clarity. From this digitalization, advanced image analysis and improved standardization are now achievable.”

Genius Digital Diagnostics enables a more seamless and dynamic collaboration across laboratories within a network, connecting pathologists with remote review so each patient can benefit from the collective knowledge of geographically dispersed experts when needed. Digital case review promises to enhance the experience for lab partners by improving workflow and accelerating review time.

“As a part of our development process, we collaborated with cytotechnologists and pathologists to ensure we were developing a new system to meet their needs,” said Michael Quick, vice president, R&D and Innovation at Hologic. “We’re always innovating so we can help our lab partners detect more diseases and save more lives every day.”

Hologic now offers the first CE-marked comprehensive cervical cancer screening portfolio from sample collection to digital diagnosis. Genius Digital Diagnostics consists of a digital imager for image acquisition, an AI algorithm for analyzing images, an image management server for storing images, and a review station for case review. The complete system is scalable, designed to fit the present and future needs of laboratories.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Forward-Looking Statements

This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s Genius™ Digital Diagnostics System. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, Genius Digital Diagnostics, ThinPrep, Aptima and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries.

SOURCE: Hologic, Inc.

Investor Contact

Michael Watts

Vice President, Investor Relations and Corporate Communications

(858) 410-8588

[email protected]

Media Contact

Jane Mazur

Vice President, Divisional Communications

(585) 355-5978

[email protected]

KEYWORDS: Massachusetts Europe United States North America

INDUSTRY KEYWORDS: Biotechnology Health Oncology

MEDIA:

Logo
Logo
Photo
Photo
Genius™ Digital Diagnostics System for Cervical Cancer Screening (Photo: Business Wire)

NXP Collaborates with Amazon Web Services (AWS) to Extend Connected Vehicle Opportunities

  • Vehicle edge-to-cloud compute solution aims to enable new automotive industry revenue opportunities
  • Sets foundation for data-driven services and enhancements that offer differentiation and cost reduction such as predictive maintenance
  • Expands access to vehicle Big Data and streamlines machine learning life cycle to accelerate vehicle development and post-sale vehicle enhancements

EINDHOVEN, The Netherlands, Nov. 17, 2020 (GLOBE NEWSWIRE) — NXP Semiconductors has announced a strategic relationship with Amazon Web Services (AWS) focused on extending the opportunities of connected vehicles. The collaboration aims to deliver a secure, edge-to-cloud compute solution for next-generation vehicles that can enable new cloud-powered services to benefit carmakers, their business partners and consumers alike.

Data will fuel future vehicle innovations as the automotive industry shifts focus from horsepower to compute power. This transformation has the potential to deliver valuable vehicle insights and drive new data-driven service revenue. Expanded access to real-time, vehicle-wide data, secure connectivity to cloud services and streamlined machine learning (ML) can accelerate the shift and enable intelligent vehicles that improve over their lifetime through remote updates.

To realize the promising services of future connected vehicles, the automotive industry requires a new type of compute solution with centralized access to vehicle-wide data that can work securely and collaboratively with the cloud. The integration of AWS edge and cloud services with NXP’s new S32G vehicle network processor for service-oriented gateways addresses the challenge.

“NXP is pleased to collaborate with AWS to help our automotive customers accelerate their digital transformation initiatives by unlocking the value of vehicle data and leveraging edge-to-cloud services,” said Henri Ardevol, executive vice president and general manager of Automotive Processing at NXP Semiconductors, “We see the opportunity to help them make impactful improvements throughout vehicle life cycles with new vehicle data insights and the ability to make continuous improvements using machine learning and over-the-air updates.”

Real-time vehicle insights can drive a myriad of new use cases and services. For example, carmakers can monitor for potential component failures before a repair is needed, prevent costly warranty repairs and recalls, optimize the supply chain and improve the customer experience by minimizing service visits.

Mobility and insurance companies can leverage expanded data to create new business models and provide cost-reduction benefits to drivers according to vehicle condition and driving behavior. Carmakers can offer attractive services that leverage vehicle sensors and other data to create new user experiences and capabilities such as remote viewing inside and around the vehicle for convenience, safety and security.

The NXP S32G processor leverages AWS IoT Greengrass and AWS IoT Core for vehicle and cloud data processing and storage, as well as Amazon SageMaker and Amazon SageMaker Neo to build, train and deploy optimized ML models. Deep learning inferencing in the vehicle is supported by NXP’s ASPICE-qualified eIQ Auto toolkit. Initial S32G platforms have been qualified for AWS IoT Greengrass, and Yocto meta-layer support is available to enable automotive customer innovations today.

NXP and AWS will present a webinar to discuss the connected vehicle solution and demonstrate a Connected Electric Vehicle (EV) Management System on November 19th at 11am EST.

About NXP Semiconductors

NXP Semiconductors N.V. enables secure connections for a smarter world, advancing solutions that make lives easier, better, and safer. As the world leader in secure connectivity solutions for embedded applications, NXP is driving innovation in the automotive, industrial & IoT, mobile, and communication infrastructure markets. Built on more than 60 years of combined experience and expertise, the company has approximately 29,000 employees in more than 30 countries and posted revenue of $8.88 billion in 2019. Find out more at www.nxp.com.

NXP and the NXP logo are trademarks of NXP B.V. All other products or service names are the property of their respective owners. All rights reserved. © 2020 NXP B.V.

For more information, please contact:

Europe/United States

Jason Deal
Tel: +44 771 5228414
[email protected]

Greater China / Asia

Ming Yue
Tel: +86 21 2205 2690
[email protected]

NXP- Automotive

NXP- Corporate

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0ce11fc2-f73a-414a-b4a6-d7de051564a1



Chi-Med Announces US$100 Million Equity Investment by CPP Investments

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Nov. 17, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (Nasdaq/AIM: HCM) today announces that it has entered into a definitive agreement for the sale of US$100 million of shares at a price equivalent to US$30 per American Depositary Share (“ADS”) via a private placement to Canada Pension Plan Investment Board (“CPP Investments”).

Mr. Christian Hogg, Chief Executive Officer of Chi-Med, said, “We are very pleased to welcome CPP Investments as a shareholder. CPP Investments’ focus on building long-term value and its experience in healthcare investing make it an important global strategic partner to Chi-Med. We look forward to building on the partnership as we work, during the next six months, to launch both surufatinib and savolitinib in China, subject to approval, as well as submit our first U.S. NDA on surufatinib.”

Mr. Agus Tandiono, Managing Director and Head of Fundamental Equities Asia at CPP Investments, said, “This placement aligns with CPP Investments’ focus on providing strategic, long-term capital to industry leading companies where we can participate in the future success of the business and help create greater value through ongoing partnership. We look forward to supporting Chi-Med’s work on innovation in oncology treatment.”

Chi-Med will receive all proceeds from this private placement of the equivalent of 3,333,334 ADSs, which will fund ongoing research and clinical development and support the further growth of its commercialization capabilities both in China and globally.

Description of Share Capital and Securities Regulation

Chi-Med has agreed to issue 16,666,670 ordinary shares, par value US$0.10 each (the “Shares”), pursuant to the private placement. The Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of Chi-Med. Each ADS represents five Shares.

The securities to be sold in the private placement will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Subject to certain conditions, the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the Shares sold in the private placement to facilitate future resales by CPP Investments. Any offering of the securities under the resale registration statement will only be made by means of a prospectus. CPP Investments has the right to appoint an observer and a representative director to the board of directors of the Company upon achieving certain ownership thresholds in the future.

This announcement, including any information included or incorporated by reference in this announcement, is for information purposes only and shall not constitute nor form part of, and should not be construed as, an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. No public offering of the securities referred to in this announcement is being made in the United States or elsewhere.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

Admission to the London Stock Exchange AIM market and Shares Outstanding After Completion

Application will be made for the Shares to be admitted to the AIM market operated by the London Stock Exchange (“Admission”). It is expected that Admission will become effective at 8:00 a.m. GMT on November 26, 2020.

Following admission of the Shares to trading on AIM, the issued share capital of Chi-Med will consist of 727,702,215 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury. The figure of 727,702,215 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

For illustrative purposes only, if the 727,702,215 ordinary shares were converted in their entirety, they would be equivalent to 145,540,443 Nasdaq-traded ADSs (each equating to five ordinary shares).

About
CPP
I
nvestments

Canada Pension Plan Investment Board (CPP Investments™) is a professional investment management organization that invests around the world in the best interests of the more than 20 million contributors and beneficiaries of the Canada Pension Plan. In order to build diversified portfolios of assets, investments in public equities, private equities, real estate, infrastructure and fixed income are made by CPP Investments. Headquartered in Toronto, with offices in Hong Kong, London, Luxembourg, Mumbai, New York City, San Francisco, São Paulo and Sydney, CPP Investments is governed and managed independently of the Canada Pension Plan and at arm’s length from governments. At September 30, 2020, the fund totalled C$456.7 billion.

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.


Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Chi-Med’s current expectations regarding future events, including its expectations regarding the use of proceeds from the transaction as well as Chi-Med’s clinical development and regulatory plans for its drug candidates and Chi-Med’s overall business strategy.
Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the funding necessary for Chi-Med’s future clinical development plans, enrollment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the timing and ability of Chi-Med to raise additional funding as needed for continued operations, and the impact of the COVID-19 pandemic on general economic, regulatory and political conditions. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

 

Investor Enquiries
 
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
   

Media Enquiries
 
Americas – Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
[email protected]
Europe – Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
[email protected]
Asia – Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), [email protected] / +852 9783 6894 (Mobile), y[email protected]
   

Nominated Advisor
 
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited +44 (20) 7886 2500



Toga Limited’s Yippi App Offers Entertainers A Venue to Showcase Their Talent During The Pandemic

PETALING JAYA, Malaysia., Nov. 16, 2020 (GLOBE NEWSWIRE) — Since June 2020, Toga Limited (OTC:TOGL) has offered entertainers a venue to showcase their talent and earn income during the Covid-19 pandemic. According to a joint statement by the International Labor Office (ILO), Food and Agriculture Organization of the United Nations (FAO), International Fund for Agricultural Development (IFAD) and World Health Organization (WHO), the COVID-19 outbreak has led to nearly half of the world’s 3.3 billion global workforce becoming at risk of losing their livelihood. Among those that have been impacted by the pandemic are performers and entertainers, whose ‘live shows’ have been postponed or cancelled. Such entertainers have been left jobless and without an income.

In line with its social responsibility initiative, Toga Limited’s social messaging app, “Yippi,” offers its users a number of global exclusive online concerts. These concerts featured emerging and established talents performing live on Yippi.

These live streaming concerts, which are exclusively available to Yippi users worldwide, also enable influencers and performing artists to campaign for the day. While performing, entertainers can earn “Yipps” from their supporters and fans, through Yippi’s tipping feature, that allows a Yippi user to tip the entertainer, with the Company retaining a percentage of the revenue generated from the tips.

“Yippi is a global platform for livestream concerts and shows,” said Toga Limited’s Chief Executive Officer Mr. Michael Toh Kok Soon. “This is an excellent opportunity to engage our Yippi users, and to meet their entertainment needs. We want to help create better experiences for them while supporting performers facing financial difficulty and hardship due to the pandemic.”

“We welcome performers to use Yippi as their performance venue, and at the same time earn a living, until live entertainment venues and events are back in operation.”

From 28th November 2020, Performers will be performing their own global exclusive online concerts on Yippi.

Additionally, during November and December 2020, Yippi has introduced a new live stream event called “Sunday Gigs” where “mystery” performers will perform live from their location at 20:30 (GMT+8) every Sunday.

Contact:
Alexander D. Henderson
TOGA LIMITED, 515 S. Flower Street, 18th Floor, Los Angeles, CA 90071
(949) 333-1603
[email protected]

Certain statements in this press release are forward-looking as defined in the Private Securities Litigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact (including, but not limited to, statements to the effect that Toga Limited or its management (the “Company”) “anticipates,” “plans,” “estimates,” “expects,” or “believes,” or the negative of these terms and other similar expressions) should be considered forward-looking statements, including, without limitation, statements regarding the Company’s guidance, outlook, growth, opportunities and long-term strategy. These statements involve certain risks and uncertainties that may cause actual results to differ materially from expectations as of the date of this release. These risks and uncertainties include, without limitation, risks associated with the impact of the COVID-19 pandemic; the Company’s ability to execute on its long-term strategy; the Company’s ability to successfully compete in its intensely competitive industry; the Company’s ability to manage its growth; the Company’s ability to maintain or improve its operating margins; the Company’s ability to identify and react to trends in consumer preferences; product supply disruptions; general economic conditions; accounting standard changes; and other factors as set forth from time to time in the Company’s Securities and Exchange Commission filings, including, without limitation, the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company intends for these forward-looking statements to speak only as of the time of this Press Release and does not undertake to update or revise them as more information becomes available, except as required by law.



SANY at bauma CHINA 2020

PR Newswire

BEIJING, Nov. 17, 2020 /PRNewswire/ — Sany will showcase a large selection of equipment, technologies, and services at bauma CHINA 2020 from November 24th to 27th, at the Shanghai New International Expo Center (SNIEC). As a leading trade fair for construction and road-building machinery industry in Asia, bauma CHINA 2020 will host 3,350 exhibitors and is projected to attract more than 220,000 visitors.

SANY exhibition area consists of an indoor exhibition pavillion (SNIEC Hall E3) and an outdoor one(D08), occupying a space of over 8,000 square meters in total. There will be 81 machines in total on display, of which more than half are debut models, representing the company’s diverse product portfolio, 29 are configured for offshore market, and over 20 are electrified models including electric excavators, electric concrete pump trucks, electric truck mixers, electric wide-body mining trucks, electric pavers, electric reach stackers, electric empty container handlers, demonstrating corporate globalization and E-mobility strategy.

Besides the exhibition on the ground, Sany will hold an online live show to bring closer the tie with colleagues, partners and customers, whether existing and/or promising, whether local or global, under the unpredictable challenging situation. The live page is available now with warm-up games: https://www.sanyglobal.com/feature/bauma-china-2020/

Sany’s first live show will kick off on November 24th, and continue through the 25th, making all valuable contents reachable for a global audience. The online event will include – Sany‘s newly launched machines, cutting-edge technologies, super sale promotion, panel discussion, visit by VR, and many more activities. What’s more, a variety of fun prizes will be sent out to the audience by lucky draw, guaranteeing a delightful and enjoyable participation.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/sany-at-bauma-china-2020-301174316.html

SOURCE SANY Group

CGG: CGG Awarded Large Offshore Malaysia Seismic Reprocessing Contracts by PTTEP

 CGG: CGG Awarded Large Offshore Malaysia Seismic Reprocessing Contracts by PTTEP

Paris,
Novem
ber
17
,
20
20

Subsurface Imaging, part of CGG’s Geoscience division, has been awarded two large-scale complex seismic reprocessing contracts by PTTEP.

PTTEP is investing in the rejuvenation of pre-existing data sets from two regions offshore Malaysia by leveraging CGG’s recognized high-end imaging technology and long-standing processing experience in SE Asia. Over the course of the next year, CGG, through its offices in Kuala Lumpur, will conduct merged reprocessing of surveys from many vintages, including towed-streamer and OBC seismic data from offshore Sabah and Sarawak. The fast-track products are expected by mid-next year and final workstation products will be delivered by the end of 2021.

PTTEP expects the resulting high-quality images will improve the definition of producing reservoirs, enable enhanced planning and drilling of future wells, and open up new plays for near-field exploration at deeper intervals. This region has a complex highly faulted subsurface where scattered gas bodies mask the target reservoir on existing data sets. To unmask the gas wipeout, remove distortions at the reservoir level and image the bounding faults, CGG will apply its latest workflow including proprietary imaging technologies, such as high-frequency full-wavefield Time-Lag FWI (HF-FWI), Q-compensating least-squares (LS-Q) Kirchhoff PSDM and LS-Q RTM, which have been fine-tuned over many similar projects in the region. These technologies will also be focused to improve imaging of the deeper exploration targets, where the objective is to improve amplitude, resolution and continuity in the mini-basins and define the steeply dipping folds underneath the main unconformity.

Sophie Zurquiyah, CEO, CGG, said: “CGG is pleased to support PTTEP, a longstanding CGG client and key player in Malaysia and the wider region, who recognizes the additional value that can be extracted from existing data sets if they are processed with our very latest imaging algorithms. CGG continues to be the industry benchmark for delivering advanced seismic imaging technology and the highest-quality service to help clients solve their complex imaging problems in order to improve production, de-risk development of existing reservoirs and identify new prospects.”

About CGG

CGG (www.cgg.com
) is a global geoscience technology leader. Employing around 4,
0
00 people worldwide, CGG provides a comprehensive range of data, products, services and equipment that supports the discovery and responsible management of the Earth’s natural resources. CGG is listed on the Euronext Paris SA (ISIN: 0013181864).

Contacts

Group Communications & Investor Relations

Christophe Barnini
Tel: + 33 1 64 47 38 11
E-Mail: [email protected]

 

 

 Attachment



CNH Industrial named leader once again in the Dow Jones Sustainability Indices

With a winning score of 89/100 the Company is confirmed as the Industry Leader in the Dow Jones Sustainability World and Europe Indices for the tenth consecutive year.

London, November 17, 2020

CNH Industrial (NYSE: CNHI /MI: CNHI) is the leader in the Machinery and Electrical Equipment Industry Group in the Dow Jones Sustainability Indices (DJSI), World and Europe, for the tenth consecutive year.

The DJSI World and DJSI Europe Indices are among the most prestigious sustainability-focused equity indices. Inclusion in these indices is exclusively for companies that are judged as exemplary in terms of their governance and economic, environmental and social performance. The DJSI World evaluation process invited 86 companies to participate in the Machinery and Electrical Equipment industry category, 13 of which were admitted to the index this year. For the DJSI Europe Index, 30 companies were invited to participate and 8 were admitted. All companies selected for consideration in the indices are evaluated by SAM, now a part of S&P Global.

“As responsible corporate citizens, we always bear in mind that our actions are reflected on our planet and the society, so we are proud to see that our dedication to be sustainable has once again resulted in us being named as Industry leader. This result confirms that we are on the right path, which calls for us to continue to improve, powering sustainable transformation,” commented Chair and Acting Chief Executive Officer, Suzanne Heywood.

In April of this year, CNH Industrial released its 2019 Sustainability Report along with the magazine A Sustainable Year, a publication for general audiences.

As of October 31, 2020, CNH Industrial was awarded ISS ESG Prime status, included in the 72 A-listers of the CDP Water Security program and in the following indexes: MSCI ESG Leaders Indexes1, ECPI Global Agriculture Liquid, ECPI World ESG Equity, ECPI Global Developed ESG Best-in-Class, ECPI Euro ESG Equity, Euronext Vigeo Europe 120, STOXX Global ESG Leaders Index, STOXX Global ESG Environmental Leaders Index, STOXX Global ESG Social Leaders Index, STOXX Global ESG Governance Leaders Index, STOXX Global ESG Impact Index, STOXX, Global Low Carbon Footprint Index, STOXX Global Reported Low Carbon Index2, Refinitiv Diversity & Inclusion Index, and Integrated Governance Index (IGI).

Additional information on Sustainability at CNH Industrial:


cnhindustrial.com/sustainability/

The 2019 Sustainability Report:


cnhindustrial.com/_Sustainability_Report_2019

A Sustainable Year:


cnhindustrial.com/a_sustainable_year_2020

Additional information on the DJSI:


sustainability-indices.com/

(1) The use by CNH Industrial of any MSCI ESG Research LLC or its affiliates (“MSCI”) data, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement, recommendation, or promotion of CNH Industrial by MSCI. MSCI services and data are the property of MSCI or its information providers, and are provided ‘as-is’ and without warranty. MSCI names and logos are trademarks or service marks of MSCI.
(2) Those listed are the main global STOXX indexes in which CNH Industrial is included.


CNH Industrial


N.V. (NYSE: CNHI /MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions.

More information can be found on the corporate website:


www.cnhindustrial.com

Sign up for corporate news alerts from the CNH Industrial Newsroom:



bit.ly/media-cnhindustrial-subscribe

Media contact:

Laura Overall    
Corporate Communications Manager
CNH Industrial              
Tel. +44 (0)2077 660 338                       
E-mail: [email protected]
www.cnhindustrial.com

Attachments